BioCryst updates ORLADEYO Japan commercialization; new royalty tier at 80% above threshold

BIOCRYST PHARMACEUTICALS INC

BioCryst Japan K.K. now handles all commercial promotion for ORLADEYO in Japan; Torii to conduct HAE disease awareness.
Royalty amended: 20% on annual Japanese sales below a prespecified threshold, 80% on sales above that threshold.
BioCryst assumes direct commercial activities for ORLADEYO in Japan via its subsidiary under updated Torii agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.